Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 205 Carcinoma, Non-Small-Cell Lung 130 Neoplasms 101 Neoplasm Metastasis 70 Breast Neoplasms 66 Ovarian Neoplasms 42 Urinary Bladder Neoplasms 37 Lung Neoplasms 37 Triple Negative Breast Neoplasms 34 Colorectal Neoplasms 30 Lymphoma, Large B-Cell, Diffuse 29 Cholangiocarcinoma 28 Biliary Tract Neoplasms 27 Carcinoma, Transitional Cell 23 Lymphoma, Non-Hodgkin 22 Adenocarcinoma 22 Recurrence 21 Lymphoma 20 Fallopian Tube Neoplasms 18 Stomach Neoplasms 15 Sarcoma 15 Parkinson Disease 4, Autosomal Dominant Lewy Body 15 Non-Muscle Invasive Bladder Neoplasms 13 Carcinoma, Pancreatic Ductal 13 Nasopharyngeal Carcinoma 12 Gallbladder Neoplasms 12 Bile Duct Neoplasms 11 Melanoma 10 Carcinoma 10 Solid Tumors 9

Interventions

Paclitaxel 3 liposomal doxorubicin 2 Carboplatin 2 1-dodecylpyridoxal 2 pembrolizumab 1 Gemcitabine 1 EP-100 membrane-disrupting peptide 1 Bevacizumab 1 AC 7700 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Cancer Recurrent × Gemcitabine × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡